Ascendis Pharma A/S (ASND)’s Financial Results Comparing With Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)

Ascendis Pharma A/S (NASDAQ:ASND) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ascendis Pharma A/S N/A 0.00 N/A -3.58 0.00
Spectrum Pharmaceuticals Inc. 109.33M 7.51 140.66M -1.16 0.00

Demonstrates Ascendis Pharma A/S and Spectrum Pharmaceuticals Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 represents Ascendis Pharma A/S (NASDAQ:ASND) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Ascendis Pharma A/S 0.00% -41.2% -37.5%
Spectrum Pharmaceuticals Inc. -128.66% 0% 0%

Volatility and Risk

Ascendis Pharma A/S is 9.00% less volatile than Standard and Poor’s 500 due to its 0.91 beta. Spectrum Pharmaceuticals Inc.’s 153.00% more volatile than Standard and Poor’s 500 which is a result of the 2.53 beta.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Ascendis Pharma A/S and Spectrum Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ascendis Pharma A/S 0 0 7 3.00
Spectrum Pharmaceuticals Inc. 0 0 3 3.00

Ascendis Pharma A/S’s consensus price target is $158, while its potential upside is 30.70%. Competitively the consensus price target of Spectrum Pharmaceuticals Inc. is $26.67, which is potential 257.99% upside. Based on the data delivered earlier, Spectrum Pharmaceuticals Inc. is looking more favorable than Ascendis Pharma A/S, analysts opinion.

Insider & Institutional Ownership

Roughly 85% of Ascendis Pharma A/S shares are owned by institutional investors while 79.7% of Spectrum Pharmaceuticals Inc. are owned by institutional investors. On the other hand, insiders owned about 1.1% of Spectrum Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ascendis Pharma A/S -2.18% 7.72% 73.07% 92.19% 84.7% 94.43%
Spectrum Pharmaceuticals Inc. -8.21% -12.36% -26.23% -35.22% -51.47% -0.34%

For the past year Ascendis Pharma A/S has 94.43% stronger performance while Spectrum Pharmaceuticals Inc. has -0.34% weaker performance.

Summary

Spectrum Pharmaceuticals Inc. beats Ascendis Pharma A/S on 6 of the 10 factors.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÂ’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.